Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Viatris Inc
(NQ:
VTRS
)
11.96
+0.06 (+0.55%)
Streaming Delayed Price
Updated: 11:44 AM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Viatris Inc
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Are defensive sectors ready to outshine growth in 2024?
January 06, 2024
Is 2024 the year defensive stocks rotate into leadership? As the year gets underway, defensives such as healthcare, energy, utilities and consumer staples lead.
Via
MarketBeat
Why Is Lung Disease Focused Theravance Biopharma Stock Trading Lower Today?
January 05, 2024
Theravance Biopharma Inc (NASDAQ: TBPH) announced results from the Phase 4 PIFR-2 study of Yupelri (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic antagonist...
Via
Benzinga
Tech Sell-Off Triggers Market Reset: Value Stocks Reach 7-Month High Versus Growth
January 03, 2024
U.S. stock market suffered worst start in two decades, tech sell-off led to cautious investor shift to value stocks, notably IUSV & IUSG ETFs + top gainers MRNA, VTRS, TNL, LVS & VAC.
Via
Benzinga
Topics
ETFs
Recap: Viatris Q3 Earnings
November 07, 2023
Via
Benzinga
2 Top Value Stocks to Buy in October
October 08, 2023
These two blue chip stocks offer top-notch yields, attractive valuations, and solid long-term prospects.
Via
The Motley Fool
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
January 01, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Regeneron Celebrates Legal Win: Court Upholds Eylea Medication Patent
December 28, 2023
Wednesday, a court ruling that found Viatris Inc's (NASDAQ:
Via
Benzinga
3 Minutes To Boost Your Earnings: 3 Stocks With Over 3% Dividend Yields In Health Care Sector From Wall Street's Most Accurate Analysts
December 27, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
A Look Into Healthcare Sector Value Stocks
December 25, 2023
Via
Benzinga
These 3 Dividend Stocks Are Undervalued Using This Key Valuation Metric
November 30, 2023
Book value is a valuable metric for discovering undervalued stocks. These 3 dividend payers are trading below book value.
Via
Talk Markets
Buy Alert: Analysts Say These 3 Growth Stocks Could Double in 2024
November 30, 2023
Often the best investments are out-of-favor and trade at silly cheap valuations. Check out three such growth stocks with huge upside.
Via
InvestorPlace
7 Low P/E Stocks Poised to Rebound
November 20, 2023
Each of these seven low P/E value stocks trades for under 10 times earnings, but could rise to a much higher valuation as sentiment improves.
Via
InvestorPlace
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal
November 18, 2023
Legend Biotech partnered its DLL3 CAR-T candidates to Novartis in a $1.2 billion agreement, with $100 million offered upfront. Novartis will own worldwide rights to develop, manufacture, and...
Via
Talk Markets
5 Value Stocks To Watch In The Healthcare Sector
November 13, 2023
Via
Benzinga
3 Large-Cap Stocks to Buy Trading Below Book Value
November 07, 2023
There aren’t too many large-cap stocks in the S&P 500 trading below book value. But here are three possibilities.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Ozempic Just Shrugged Off a Challenge From Viatris. What Does This Mean for Investors?
October 31, 2023
Viatris now faces a narrower path to commercializing a generic copy of Ozempic.
Via
The Motley Fool
Viatris Just Sold Off 3 Key Segments. Is It Still a Buy?
October 13, 2023
There's a chance shareholders won't notice any difference.
Via
The Motley Fool
2 Healthcare Dividend Stocks You'd Regret Not Buying on the Dip
October 08, 2023
These stocks may not be for everyone, but income-seekers might find what they're looking for in them.
Via
The Motley Fool
Obesity Drug Wegovy's Triumph to Catapult Novo Holdings In Golden Era Of Wealth Boost
October 03, 2023
Novo Holdings, the controlling shareholder of Novo Nordisk A/S (NYSE: NVO), is bracing for a significant influx of capital stemming from the thriving success of the weight-loss drug Wegovy.
Via
Benzinga
Earnings Scheduled For November 7, 2023
November 07, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter.
Via
Benzinga
'Airbnb Has Foundational Cracks', Disney+ Follows Netflix On Subscription Sharing Crackdown, Microsoft's Nadella Criticizes Google's Exclusive Content Deals: Today's Top Stories
October 03, 2023
Benzinga
Via
Benzinga
Novo Nordisk Weight Loss Drug Patent Battle Against Viatris - Emerges As Winner
October 03, 2023
Novo Nordisk A/S (NYSE: NVO) successfully defended two pivotal patent claims linked to the main ingredient in its popular weight-loss and diabetes drugs,
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Viatris Stock Bounds Higher As Divestitures Reach Nearly $7 Billion
October 02, 2023
The company is retaining the rights to specific over-the-counter drugs in some markets.
Via
Investor's Business Daily
Viatris Phase 1 Asset Divestiture Story: Plans To Sell Certain OTC Products, Women's Healthcare Business & More
October 02, 2023
Viatris Inc (NASDAQ: VTRS) disclosed multiple deals to sell remaining assets to conclude Phase 1 of planned asset disposition by
Via
Benzinga
Could Viatris Stock Help You Become a Millionaire?
September 30, 2023
Viatris' broad portfolio gives the business lots of stability and plenty of opportunities -- but is there enough there for the stock to be a great long-term investment?
Via
The Motley Fool
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields
September 27, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Despite Efforts, Vulnerable Patients Still Face Barriers to Essential Medicines, Says New Report
September 26, 2023
Despite significant initiatives by generic drug companies to broaden access to vital medicines, many vulnerable patients remain underserved, according to findings from a new study from the Access to...
Via
Benzinga
NASDAQ: VTRS Shareholder Notice Investigation over Potential Wrongdoing by Certain Directors of Viatris Inc.
September 22, 2023
San Diego, CA -- (SBWIRE) -- 09/22/2023 -- Certain directors of Viatris Inc.are under investigation concerning potential breaches of fiduciary duties.
Via
SBWire
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
September 22, 2023
The analyst illustrated how the dominant force in stock market returns for 2023 has been the "Magnificent 7."
Via
Benzinga
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
September 14, 2023
These stocks offer some mouth-watering payouts.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.